Global Inflammation Think Tank
"Inflammation: Shared Pathways in Diverse Diseases" is a unique multidisciplinary event scheduled to take place on Tuesday, May 4, 2021, and Wednesday, May 5, 2021, that will unite inflammation specialists from leading global institutions.
This global inflammation meeting is organized by the Cura Foundation and the Vatican's Pontifical Council for Culture, and with the educational support of the Worldwide Network for Innovation in Clinical Education and Research (WNICER). It will focus on Building Bridges Between Disciplines to Advance Knowledge and Public Health. The goals of this gathering are to better understand inflammation in diverse diseases, provide a structured assessment for its evaluation and improve therapeutic approaches to modulate inflammatory pathways and processes.
This think tank will include luminaries from different fields with the aim to transcend usual boundaries between specialties, to hasten scientific advances, and accelerate translation to improved health as Inflammation provide a common set of pathways that generate diseases in multiple fields and are being harnessed for novel treatments.
The Cura Foundation (“Cura” or the “Foundation”) is a nonsectarian, nonpartisan, public 501(c)(3) organization with a mission is to improve human health globally. Cura’s objective is to streamline health care delivery and optimize access to care to prevent and vanquish disease, reduce human suffering and increase the quality of life around the world. We aim to advance the development of breakthrough medical technologies, promote preventative measures, encourage interdisciplinary approaches to medicine, improve access to innovation and eliminate social disparities in health care.
At Cura, we #UniteToPrevent and #UniteToCure.
WNICER (Worldwide Network for Innovation in Clinical Education and Research) is a multinational network with the goal to impact chronic conditions through clinical research in order to produce evidence-based trials and interventions that increase our knowledge of health and disease, improving the quality of our health care, and the development of devices and therapies that can directly benefit the patient. WNICER is committed to implementing programs that aim to shorten the time from discovery to patient application with translational research, innovative clinical trials and implementation strategies that impact clinical care that are all supported by a strong continuing medical education program.
Peter Munk Chair in Multinational Clinical Trials; Director, Heart & Stroke/Richard Lewar Centre of Excellence; Vice-Chair, Research and Professor of Medicine, Department of Medicine, University of Toronto
Cardiovascular Specialist, Brigham and Women’s Hospital and Mallinckrodt Professor of Medicine, Harvard Medical School
Professor of Medicine and Cardiology, The Icahn School of Medicine at Mount Sinai
President, Cura Foundation and Stem for Life, and Vice President and Director, Science and Faith Foundation (STOQ)
The Rennert Chair of Aging Research, Professor of Medicine and Genetics and
Director, Nathan Shock Center of Excellence in the Biology of Aging, Albert Einstein College of Medicine
Director, Charles Bronfman Institute for Personalized Medicine and Ward-Coleman Chair for Translational Genetics, Icahn School of Medicine at Mount Sinai
Full Professor of Nutrition,
Sorbonne University; Institut National de la Santé et de la Recherche Médicale (INSERM) and Assistance Publique – Hôpitaux de Paris, Paris (AP-HP)
Professor of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm
Distinguished University Professor and Past President,
MD Anderson Cancer Center
Professor of Medicine, Chief, Division of Pulmonary, Critical Care, and Sleep Medicine and Senior Director, Clinical Research Strategy and Growth, University of Arizona College of Medicine-Phoenix; Physician Executive Director, Banner - University Lung Institute
Assistant Professor of Medicine and Frances and Kenneth Eisenberg Emerging Scholar, Taubman Medical Research Institute University of Michigan Medical School
Professor, Department of Medicine, Karolinska Institute and the Royal Swedish Academy of Sciences
Istituto Clinico Humanitas;
Professor of Clinical Immunology, University of Lyon, France
Chief of Cardiovascular Medicine, Director of Case Cardiovascular Research Institute, Herman K. Hellerstein MD Endowed Chair in Cardiovascular Research, and Professor of Medicine, Case Western Reserve University, University Hospitals (UH)
Director, Mario Negri Institute for Pharmacological Research, Professor of Nephrology, University of Milan, Italy
Eugene Braunwald Professor of Medicine, Harvard Medical School and
Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital
Director, Emory-Georgia Tech Healthcare Innovation Program and Medical Director, The Marcus Foundation
Director, Sanders-Brown Center on Aging, University of Kentucky
Professor & Chief of Molecular Medicine, UCLA School of Medicine, Director, Institute for Infection & Immunity, Lundquist Institute at Harbor-UCLA and Chair, Medical Sciences, Guthy-Jackson Charitable Foundation